Cameron S Metcalf1, Peter J West1, Kyle E Thomson1, Sharon F Edwards1, Misty D Smith1,2, H Steve White3, Karen S Wilcox1. 1. Anticonvulsant Drug Development Program, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, U.S.A. 2. School of Dentistry, University of Utah, Salt Lake City, Utah, U.S.A. 3. Department of Pharmacy, University of Washington, Seattle, Washington, U.S.A.
Abstract
OBJECTIVE: The mouse 6 Hz model of psychomotor seizures is a well-established and commonly used preclinical model for antiseizure drug (ASD) discovery. Despite its widespread use both in the identification and differentiation of novel ASDs in mice, a corresponding assay in rats has not been developed. We established a method for 6 Hz seizure induction in rats, with seizure behaviors similar to those observed in mice including head nod, jaw clonus, and forelimb clonus. METHODS: A convulsive current that elicits these seizure behaviors in 97% of rats (CC97 ) was determined using a Probit analysis. Numerous prototype ASDs were evaluated in this model using stimulus intensities of 1.5× and 2× the CC97 , which is comparable to the approach used in the mouse 6 Hz seizure model (e.g., 32 and 44 mA stimulus intensities). The ASDs evaluated include carbamazepine, clobazam, clonazepam, eslicarbazepine, ethosuximide, ezogabine, gabapentin, lacosamide, lamotrigine, levetiracetam, phenobarbital, phenytoin, rufinamide, tiagabine, topiramate, and sodium valproate. Median effective dose (ED50 ) and median toxic (motor impairment) dose (TD50 ) values were obtained for each compound. RESULTS: Compounds that were effective at the 1.5 × CC97 stimulus intensity at protective index (PI) values >1 included clobazam, ethosuximide, ezogabine, levetiracetam, phenobarbital, and sodium valproate. Compounds that were effective at the 2 × CC97 stimulus intensity at PI values >1 included ezogabine, phenobarbital, and sodium valproate. SIGNIFICANCE: In a manner similar to the use of the mouse 6 Hz model, development of a rat 6 Hz test will aid in the differentiation of ASDs, as well as in study design and dose selection for chronic rat models of pharmacoresistant epilepsy. The limited number of established ASDs with demonstrable efficacy at the higher stimulus intensity suggests that, like the mouse 6 Hz 44 mA model, the rat 6 Hz seizure model may be a useful screening tool for pharmacoresistant seizures. Wiley Periodicals, Inc.
OBJECTIVE: The mouse 6 Hz model of psychomotor seizures is a well-established and commonly used preclinical model for antiseizure drug (ASD) discovery. Despite its widespread use both in the identification and differentiation of novel ASDs in mice, a corresponding assay in rats has not been developed. We established a method for 6 Hz seizure induction in rats, with seizure behaviors similar to those observed in mice including head nod, jaw clonus, and forelimb clonus. METHODS: A convulsive current that elicits these seizure behaviors in 97% of rats (CC97 ) was determined using a Probit analysis. Numerous prototype ASDs were evaluated in this model using stimulus intensities of 1.5× and 2× the CC97 , which is comparable to the approach used in the mouse 6 Hz seizure model (e.g., 32 and 44 mA stimulus intensities). The ASDs evaluated include carbamazepine, clobazam, clonazepam, eslicarbazepine, ethosuximide, ezogabine, gabapentin, lacosamide, lamotrigine, levetiracetam, phenobarbital, phenytoin, rufinamide, tiagabine, topiramate, and sodium valproate. Median effective dose (ED50 ) and median toxic (motor impairment) dose (TD50 ) values were obtained for each compound. RESULTS: Compounds that were effective at the 1.5 × CC97 stimulus intensity at protective index (PI) values >1 included clobazam, ethosuximide, ezogabine, levetiracetam, phenobarbital, and sodium valproate. Compounds that were effective at the 2 × CC97 stimulus intensity at PI values >1 included ezogabine, phenobarbital, and sodium valproate. SIGNIFICANCE: In a manner similar to the use of the mouse 6 Hz model, development of a rat 6 Hz test will aid in the differentiation of ASDs, as well as in study design and dose selection for chronic rat models of pharmacoresistant epilepsy. The limited number of established ASDs with demonstrable efficacy at the higher stimulus intensity suggests that, like the mouse 6 Hz 44 mA model, the rat 6 Hzseizure model may be a useful screening tool for pharmacoresistant seizures. Wiley Periodicals, Inc.
Authors: Meir Bialer; Svein I Johannessen; René H Levy; Emilio Perucca; Torbjörn Tomson; H Steve White Journal: Epilepsy Res Date: 2010-12 Impact factor: 3.045
Authors: Grzegorz Bulaj; Brad R Green; Hee-Kyoung Lee; Charles R Robertson; Karen White; Liuyin Zhang; Marianna Sochanska; Sean P Flynn; Erika Adkins Scholl; Timothy H Pruess; Misty D Smith; H Steve White Journal: J Med Chem Date: 2008-12-25 Impact factor: 7.446
Authors: H Steve White; Erika A Scholl; Brian D Klein; Sean P Flynn; Timothy H Pruess; Brad R Green; Liuyin Zhang; Grzegorz Bulaj Journal: Neurotherapeutics Date: 2009-04 Impact factor: 7.620
Authors: Ariadna Amador; Christopher D Bostick; Heather Olson; Jurrian Peters; Chad R Camp; Daniel Krizay; Wenjuan Chen; Wei Han; Weiting Tang; Ayla Kanber; Sukhan Kim; JiaJie Teoh; Megha Sah; Sabrina Petri; Hunki Paek; Ana Kim; Cathleen M Lutz; Mu Yang; Scott J Myers; Subhrajit Bhattacharya; Hongjie Yuan; David B Goldstein; Annapurna Poduri; Michael J Boland; Stephen F Traynelis; Wayne N Frankel Journal: Brain Date: 2020-07-01 Impact factor: 13.501
Authors: Zachery Koneval; Kevin M Knox; Ali Memon; Dannielle K Zierath; H Steve White; Melissa Barker-Haliski Journal: Epilepsia Date: 2020-08-05 Impact factor: 5.864
Authors: Xiaoyang Li; Richard A Himes; Lyndsey C Prosser; Charleston F Christie; Emma Watt; Sharon F Edwards; Cameron S Metcalf; Peter J West; Karen S Wilcox; Sherine S L Chan; C James Chou Journal: J Med Chem Date: 2020-05-22 Impact factor: 7.446
Authors: Kyle E Thomson; Cameron S Metcalf; Thomas G Newell; Jennifer Huff; Sharon F Edwards; Peter J West; Karen S Wilcox Journal: Epilepsia Date: 2020-05-18 Impact factor: 6.740